Gilead Terminates Phase II Clinical Trial of GS 9450 in Patients With Chronic Hepatitis C
April 19 2010 - 8:30PM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the company
is stopping its ongoing Phase II clinical trial of GS 9450, an
investigational caspase inhibitor, in patients with chronic
hepatitis C. This decision follows reports of significant
laboratory abnormalities and adverse events in a number of clinical
study participants.
Patient safety is Gilead’s top priority, and the company has
therefore made the decision to halt this study immediately. Gilead
will be conducting a thorough review of all available data to
assess future clinical development of the compound.
About Gilead
Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Australia.
Forward-Looking
Statement
This press release includes forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of
1995, that are subject to risks, uncertainties and other factors
that could cause actual results to differ materially from those
referred to in the forward-looking statements, including risks that
further analysis of the laboratory abnormalities, adverse events
and other data obtained to date may not support the continued
development of GS 9450. The reader is cautioned not to rely on
these forward-looking statements. Gilead directs readers to its
Annual Report on Form 10-K for the year ended December 31, 2009.
Gilead claims the protection of the Safe Harbor contained in the
Private Securities Litigation Reform Act of 1995 for
forward-looking statements. All forward-looking statements are
based on information currently available to Gilead, and Gilead
assumes no obligation to update any such forward-looking
statements.
For more information on Gilead
Sciences, please visit the company's website at www.gilead.com or
call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024